Cancers, Vol. 10, Pages 53: A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas
Cancers, Vol. 10, Pages 53: A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas
Cancers doi: 10.3390/cancers10020053
Authors:
Varun Monga
Umang Swami
Munir Tanas
Aaron Bossler
Sarah L. Mott
Brian J. Smith
Mohammed Milhem
Epigenetic events and genetic alterations under the control of the tumor microenvironment potentially mediate tumor induced angiogenesis involved in soft tissue sarcoma (STS) metastasis. Addition of antiangiogenic agent, such as bevacizumab, to standard chemotherapy in treatment of sarcoma has been studied in clinical trials, but most of the findings have not supported its use. We hypothesized the existence of an epigenetically mediated “angiogenic switch”, and the tumor microenvironment, prevents bevacizumab from truly blocking angiogenesis. The addition of valproic acid (VPA), a weak histone deacetylase inhibitor, and bevacizumab, a monoclonal antibody against vascular endothelial growth factor, together with the cytotoxic effects of gemcitabine and docetaxel, may enhance responses and alter chemoresistance. This was designed as a phase I/II trial with primary endpoints including safety of the treatment combination and tumor response. Unresectable or metastatic sarcoma patients >18 years of age, irrespective of number of prior treatments, received VPA 40 mg/kg orally for 5 days prior to day 1, bevacizumab at 15 mg/kg...
Source: Cancers - Category: Cancer & Oncology Authors: Varun Monga Umang Swami Munir Tanas Aaron Bossler Sarah L. Mott Brian J. Smith Mohammed Milhem Tags: Article Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinosarcoma | Chemotherapy | Clinical Trials | Docetaxel | Genetics | Leiomyosarcoma | Sarcomas | Soft Tissue Sarcoma | Study | Taxotere | Undifferentiated Carcinoma